Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adalimumab in Patients With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate

NCT02393378 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02393378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02393378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adalimumab in Patients With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Terminated
Start date
April 8, 2015
Completion date
November 16, 2016
Enrollment
7 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis